ODAC's Vote For Another Trial Could Be Death Knell For Vion's Onrigin

Vion will probably have to cut its losses on the elderly acute myeloid leukemia drug Onrigin (laromustine) after an FDA panel voted unanimously Sept. 1 that another randomized trial needs to be conducted before the drug can be approved